How do we balance the public health benefit of sharing clinical study information with the need to respect patient privacy and encourage continued innovation?

PHARMA: 8/20/13

Contributors Respond

The debate around clinical trial transparency is certainly nothing new, with some arguing that the Clinicaltrials.gov registration requirement in the Food and Drug Administration Amendments Act (FDAAA) isn’t being properly implemented and that more transparency (and oversight) is needed to satisfy full public disclosure and address the issue.

Unfortunately, it’s just not that simple. Read more